Access to atrial flow regulators for implantation in critically ill children via the US Food and Drug Administration's emergency use pathway.

Authors

Christopher Iskander, Mehmet Kucuk, Anne Taylor, Ryan Leahy, Jenny E Zablah, Gareth J Morgan

Published in

The Journal of invasive cardiology. Jul 28, 2026. Epub Jul 28, 2026.

Abstract

The authors conducted a review of the US Food and Drug Administration's (FDA) emergency use authorization (EUA) pathway as a mechanism to use the Occlutech Atrial Flow Regulator (AFR) (Occlutech International AB) for critically ill pediatric patients with congenital heart disease.
The authors describe 8 pediatric patients in whom the EUA pathway was activated to permit AFR implantation and provide potentially lifesaving therapy.
Emergency authorization was granted for each of the 8 cases with successful implantation of the AFR. There were 2 cases in which the patient required a repeat catheterization for thrombus on the device, but all 8 patients were able to progress their care. These cases demonstrate the feasibility of the EUA pathway to access emerging technologies for pediatric patients.
The Occlutech AFR may provide an important therapeutic option for critically ill children with congenital heart disease. The EUA pathway can facilitate timely access to unapproved but potentially beneficial technologies when no satisfactory approved alternatives exist.

PMID:
42525841
Bibliographic data and abstract were imported from PubMed on 30 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.